CONTEXT: Cushing's Disease (CD) alters fat distribution, muscle mass, adipokine profile, and cardiovascular risk factors. It is not known whether remission entirely reverses these changes. OBJECTIVES: Our objective was to determine whether the adverse body composition and cardiovascular risk profile in CD change after remission. DESIGN, SETTING, AND PATIENTS: Fourteen CD patients were studied prospectively: before surgery (active disease) and again postoperatively 6 months after discontinuing oral glucocorticoids (remission). Whole-body magnetic resonance imaging was used to examine lean and fat tissue distributions. OUTCOME MEASURES: Body composition (skeletal muscle and fat in the visceral, bone marrow, sc, and inter-muscular compartments) and cardiovascular risk factors (serum insulin, glucose, leptin, high-molecular-weight adiponectin, C-reactive protein, and lipid profile) were measured in active CD and remission (mean 20 months after surgery). RESULTS: Remission decreased visceral, pelvic bone marrow, sc (including trunk and limb sc), and total fat; waist circumference; and weight (P < 0.05). Remission altered fat distribution, resulting in decreased visceral/total fat (P = 0.04) and visceral fat/skeletal muscle ratios (P = 0.006). Remission decreased the absolute muscle mass (P = 0.015). Cardiovascular risk factors changed: insulin resistance, leptin, and total cholesterol decreased (P < 0.05), but adiponectin, C-reactive protein, and other lipid measures did not change. CONCLUSIONS: CD remission reduced nearly all fat depots and reverted fat to a distribution more consistent with favorable cardiovascular risk but decreased skeletal muscle. Remission improved some but not all cardiovascular risk markers. Remission from CD dramatically improves body composition abnormalities but may still be associated with persistent cardiovascular risk.
CONTEXT: Cushing's Disease (CD) alters fat distribution, muscle mass, adipokine profile, and cardiovascular risk factors. It is not known whether remission entirely reverses these changes. OBJECTIVES: Our objective was to determine whether the adverse body composition and cardiovascular risk profile in CD change after remission. DESIGN, SETTING, AND PATIENTS: Fourteen CDpatients were studied prospectively: before surgery (active disease) and again postoperatively 6 months after discontinuing oral glucocorticoids (remission). Whole-body magnetic resonance imaging was used to examine lean and fat tissue distributions. OUTCOME MEASURES: Body composition (skeletal muscle and fat in the visceral, bone marrow, sc, and inter-muscular compartments) and cardiovascular risk factors (serum insulin, glucose, leptin, high-molecular-weight adiponectin, C-reactive protein, and lipid profile) were measured in active CD and remission (mean 20 months after surgery). RESULTS: Remission decreased visceral, pelvic bone marrow, sc (including trunk and limb sc), and total fat; waist circumference; and weight (P < 0.05). Remission altered fat distribution, resulting in decreased visceral/total fat (P = 0.04) and visceral fat/skeletal muscle ratios (P = 0.006). Remission decreased the absolute muscle mass (P = 0.015). Cardiovascular risk factors changed: insulin resistance, leptin, and total cholesterol decreased (P < 0.05), but adiponectin, C-reactive protein, and other lipid measures did not change. CONCLUSIONS:CD remission reduced nearly all fat depots and reverted fat to a distribution more consistent with favorable cardiovascular risk but decreased skeletal muscle. Remission improved some but not all cardiovascular risk markers. Remission from CD dramatically improves body composition abnormalities but may still be associated with persistent cardiovascular risk.
Authors: Wei Shen; ZiMian Wang; Haiying Tang; Stanley Heshka; Mark Punyanitya; Shankuan Zhu; Jianbo Lei; Steven B Heymsfield Journal: Obes Res Date: 2003-02
Authors: P-H Ducluzeau; P Manchec-Poilblanc; V Roullier; E Cesbron; J Lebigot; S Bertrais; C Aubé Journal: Clin Radiol Date: 2010-06-19 Impact factor: 2.350
Authors: L Lenchik; T C Register; F C Hsu; K Lohman; B J Nicklas; B I Freedman; C D Langefeld; J J Carr; D W Bowden Journal: Bone Date: 2003-10 Impact factor: 4.398
Authors: Heidi S Berner; Staale P Lyngstadaas; Axel Spahr; Marta Monjo; Liv Thommesen; Christian A Drevon; Unni Syversen; Janne E Reseland Journal: Bone Date: 2004-10 Impact factor: 4.398
Authors: A G Rockall; S A Sohaib; D Evans; G Kaltsas; A M Isidori; J P Monson; G M Besser; A B Grossman; R H Reznek Journal: Eur J Endocrinol Date: 2003-12 Impact factor: 6.664
Authors: A G Rockall; S A Sohaib; D Evans; G Kaltsas; A M Isidori; J P Monson; G M Besser; A B Grossman; R H Reznek Journal: Eur J Endocrinol Date: 2003-12 Impact factor: 6.664
Authors: A Scillitani; G Mazziotti; C Di Somma; S Moretti; A Stigliano; R Pivonello; A Giustina; A Colao Journal: Osteoporos Int Date: 2015-03-06 Impact factor: 4.507
Authors: Mauro Zamboni; Andrea P Rossi; Francesco Fantin; Simona L Budui; Elena Zoico; Giulia A Zamboni; Gloria Mazzali Journal: Curr Obes Rep Date: 2014-12
Authors: P Luo; A Dematteo; Z Wang; L Zhu; A Wang; H-S Kim; A Pozzi; J M Stafford; J M Luther Journal: Diabetologia Date: 2013-01-12 Impact factor: 10.122
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958
Authors: M A Minetto; C Caresio; M Salvi; V D'Angelo; N E Gorji; F Molinari; G Arnaldi; S Kesari; E Arvat Journal: J Endocrinol Invest Date: 2018-11-15 Impact factor: 4.256